Kornimate/medical-research-clean huggingface dataset:
the cedars-sinai smidt heart institute takotsubo registry & proteomic study

Conditions: Takotsubo Cardiomyopathy

Summary: the cedars-sinai shi takotsubo registry and proteomic study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of takotsubo registry protocol. subjects will also be invited to provide a blood sample utilizing a mitra kit sent to their homes. researchers from the barbra streisand women's heart center will analyze registry data to identify takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted takotsubo treatments.

registry outreach will begin with an informational and inspirational website and will utilize social media and patient-driven activism through facebook, blogs and twitter modalities that have demonstrated efficiencies in other patient-centered research efforts. subjects will upload specific clinical materials into cedar-sinai's web-enabled cloud storage and which will be screened by trained smidt heart institute physicians. the registry utilizes on-line, e-consent and enrollment connected to a redcap database that will allow efficient data input for analysis. all potential subjects who have been diagnosed with takotsubo or have been informed by their physician that they meet diagnosis criteria, will need to provide information for review that includes: hospitalization records, from the time of takotsubo event, with laboratory data (particularly -- troponin level), ecg and cta. registrants will be asked to respond to annual update surveys. the goal is to accurately understand the prevalence, recurrence and prospective status of the takotsubo, to determine which individuals are at risk of reoccurrence or subsequent adverse event and to determine potential treatment targets to develop therapeutic strategies primary: * to establish a large usa-based database for patients with takotsubo with a convenient and easy to use on-line patient-advocate registry using digital media marketing, box cloud data access and storage, accurate case adjudication, and automated follow-up. * participants will also be offered the option of participating in the takotsubo proteomic registry by providing remote ambulatory mitra blood samples. secondary: • to establish a clinical trial platform for patient-centered point-of-care trials to improve diagnostics, clinical care and outcomes.

Eligibility criteria:
inclusion criteria: * have received a diagnosis of takotsubo from their physician and consent to enroll * submit full medical records needed for takotsubo adjudication exclusion criteria: * younger than 18 years * unable to provide informed consent * unable to provide the necessary documentation needed for screening purposes

Keywords: takotsubo
timing of vte prophylaxis in tbi

Conditions: TBI (Traumatic Brain Injury); VTE (Venous Thromboembolism)

Summary: this study compares the efficacy and complication rates of early (24 hours) versus late (72 hours) vte prophylaxis administration to tbi patients. patients in both treatment groups will be monitored for development of vte as well as complications from bleeding after commencement of vte prophylaxis.

this a randomized prospective study that compares the efficacy and complication rates of early (24 hours) versus late (72 hours) vte prophylaxis administration to tbi patients. patients who are identified as having an intracranial injury will be randomized to early versus late vte prophylaxis using a 1:1 random numbers allocation. patients in both treatment groups will be monitored for development of vte, primarily with scheduled duplex ultrasound studies of the lower extremities. any clinical suspicion of vte will also be investigated with duplex ultrasound and/or ct angiogram of the chest. patients will be monitored for development of complications from bleeding post commencement of vte prophylaxis. intracranial bleeding complications will be monitored by physical examination and ct scanning of the head when indicated. patients who undergo craniotomy or craniectomy will have vte prophylaxis started 72 hours post-surgery and will undergo ct scan of the head (to assure bleeding stabilization) prior to administration of vte prophylaxis.

Eligibility criteria:
inclusion criteria: * traumatic brain injury * intracranial hemorrhage on ct scan exclusion criteria: * under the age of 18 * pregnant * die within 24 hours of admission * hospital stay less than 5 days * contraindications to enoxaparin or heparin * coagulopathy at 24 hours post-injury defined as inr\>1.6 aptt\>2x normal, or platelet counts\<50k * known history of vte
effects of n-acetyl cysteine during percutaneous coronary intervention

Conditions: Coronary Artery Disease

Summary: the aim of this study is to evaluate the effects of n-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.


Eligibility criteria:
inclusion criteria: * patients \> 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (mehran score ≥ 5) exclusion criteria: * primary percutaneous coronary intervention * low risk for contrast induced nephropathy (mehran score \< 5) * use of nephrotoxic agents (nsaids, aminoglycosides,recent contrast injection...) * infection * pregnancy, lactation * renal failure requiring dialysis * hepatic failure * history allergy for nac * history of asthma * chronic nitrate usage * malignancy * use of corticosteroids * leukocytosis,thrombocytosis,anemia * blood pressure of \>180/100mmhg despite anti-hypertensive therapy

Keywords: n-acetyl cysteine percutaneous coronary intervention
changes in radicular pain and pain modulation

Conditions: Back Pain; Back Pain With Radiation

Summary: the objectives of this study are: 1)to investigate the difference in pain modulatory mechanisms using quantitative sensory testing (qst) between healthy controls and patients with radicular leg pain due to nerve root compression. 2) to investigate the association between changes in radiating leg pain and pain modulation among the patient group.

few studies have investigated pain modulatory mechanisms using qst in patients with lumbar radiculopathy due to nerve root compression. knowledge about the association between changes in the experience of pain and changes measures of pain modulation is to our knowledge limited. the results could potentially contribute to knowledge about mechanisms involved in lumbar radiculopathy and facilitate future studies. the hypotheses of the study are: 1) measures of pain modulation will be less efficient among patients with lumbar radiculopathy showing reduced pain inhibition and facilitated temporal summation compared to healthy controls. 2) improvements in pain modulation will be associated with improvements in clinical pain outcomes

Eligibility criteria:
inclusion criteria: patient group * radiating leg pain due to nerve root compression verified by mri * clinical findings in accordance with mri findings * average leg pain ≥ 3/10 on a numeric pain rating scale controls * no current or previous history of ongoing musculoskeletal pain exclusion criteria: applies for both groups. * other specific medical conditions e.g. rheumatologic disease, diabetes or vascular diseases. * pregnancy

Keywords: low back pain radiculopathy conditioned pain modulation temporal summation
coagulation profile in patients undergoing coronary angiography and percutaneous coronary intervention

Conditions: Chronic Coronary Insufficiency; Smoking

Summary: the activated clotting time (act), global thrombosis test (gtt-3), platelet inhibition p2y12 (verifynow) test and serum coagulation factors will be measured in patients undergoing coronary angiography (ca) and percutaneous coronary intervention (pci).

the activated clotting time (act), global thrombosis test (gtt-3) and platelet inhibition p2y12 (verifynow) test and serum coagulation factors will be measured in patients undergoing coronary angiography (ca) and percutaneous coronary intervention (pci) - 20 smoking and 20 non-smoking.the measurements will take place: before coronary angiography (ca), 10 minutes after unfractionated heparin (hnf), 2h after ca, 6h after ca, 30 days after ca

Eligibility criteria:
inclusion criteria: * patients scheduled do ca \>18 years old exclusion criteria: * pregnancy * previous treatment with p2y12 inhibitors, novel oral anticoagulants (noac) or warfarin acenocoumarol in last 24 hours

Keywords: coronary angiography activated clotting time platelet inhibition
analgesia and cancer recurrence lung cancer resection

Conditions: Recurrence Tumor; Opioid Use, Unspecified; Analgesia; Thoracic Surgery

Summary: the choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for stage i non-small cell lung cancer. the investigators retrospectively reviewed the records of patients who underwent lung resection for stage i nsclc between january 2005 and december 2012. patients received analgesia either by peridural (peri group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (ev group). follow-up was concluded in august 2019. the five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.


Eligibility criteria:
inclusion criteria: * age ≥ 18 yrs * patients who underwent lung resection for stage i nsclc between january 2005 and december 2012 exclusion criteria: * age\<18aa * pregnancy * day hospital patients

Keywords: recurrence tumor opioid use analgesia thoracic surgery
shr6390 plus nab-paclitaxel and gemcitabine in advanced/metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the study is being conducted to evaluate the efficacy, safety and tolerability of shr6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.

this is an open-label, prospective, single-center, single-arm, simon's two-stage design phase ii study for unresectable advanced or metastatic pancreatic ductal adenocarcinoma (pdac) subjects treated with shr6390 plus nab-paclitaxel and gemcitabine. in this research study, the main objectives include: 1. evaluate objective response rate in patients with pancreatic cancer receiving shr6390 plus nab-paclitaxel and gemcitabine. 2. assess adverse side effects associated with the combination of shr6390 with nab-paclitaxel and gemcitabine.

Eligibility criteria:
inclusion criteria: 1. male or female of 18 to 75 years old; 2. subjects are diagnosed with histologically confirmed unresectable advanced or metastatic pancreatic ductal adenocarcinoma with at least one measurable lesion according to the recist 1.1 standard (the ct scan length of the tumor lesion \> 10 mm); 3. subjects are naïve to systemic treatment; 4. eastern cooperative oncology group (ecog) performance status of 0 or 1; 5. life expectancy ≥12 weeks; 6. adequate organ performance based on laboratory blood tests; 7. the toxicity of the previous treatment has been restored to ≤1 level (if there is surgery, the wound has completely healed); 8. women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation; 9. normal swallowing function; 10. willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures. exclusion criteria: 1. had other active malignant tumors within 5 years before entering the study; 2. confirmed or suspicious new metastatic lesion in brain; 3. subjects are allergy to experimental drugs or any excipients; 4. coagulation disorders (inr\>1.5, aptt\>uln); 5. severe pleural effusion or ascites; 6. severe and uncontrolled medical diseases, acute infections; recent history of major surgery for myocardial infarction (within 3 months); 7. subjects combined with other anti-tumor drugs; 8. chronic diarrhea or intestinal obstruction; 9. pregnant or lactating women; fertile subjects who are unwilling or unable to take effective contraceptive measures; 10. subjects in any trial drug treatment; 11. severe mental disorder; 12. other situations that investigators considered should be excluded.
examining clinical research participation for substance abuse disorder patient

Conditions: Substance Abuse Disorder

Summary: clinical study participation percentages haven't always been fully representative of a given demographic. the goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. the data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future substance abuse disorder patients during clinical trials.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. * participant has a diagnosis of substance abuse disorder. * willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. exclusion criteria: * patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. * pregnant or lactating woman * known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results

Keywords: substance abuse disorder
predictive outcomes for selective thumb carpometacarpal joint denervation

Conditions: CMC Arthritis

Summary: background: the thumb (or first) carpometacarpal (cmc) joint is commonly affected by osteoarthritis. literature has reported a prevalence of 15% in women and 7% in men. first cmc joint osteoarthritis can present with decreased grip strength, pain, instability and inability to engage in routine daily activities. definitive management is with surgery, however these are associated with known risks and increased weight times for the patient. first cmc joint denervation surgery is supported in the literature as a safe and effective approach to treat pain, strength, and thumb opposition which still allows for definitive surgery to be performed later if the arthritis progressed or if the pain returned later after the surgery. objectives: (1) evaluate the effectiveness of the neurectomy in patients with with cmc arthritis with respect to pain relief, functional parameters, and quick disabilities of the arm, shoulder and hand (quickdash) scores; (2) to determine whether pain relief with selective nerve blocks are predictive of the outcome of the combined neurectomy; and (3) to determine whether improvement in grip strength following selective blocks is predictive of final grip strength and outcome following neurectomy. methods: patients referred to the plastic surgery clinic for assessment of symptomatic first cmc joint osteoarthritis will be provided options for standard treatment or denervation procedure. patients who agree to denervation will undergo local anesthetic block at their initial consult. at their initial consultation as well as at the 2-week, 3-month, 6-month, 12-month and 24-month post-surgical follow-up, patients will complete a quickdash, kapandji score, pain scores, 2-point discrimination and grip/key/3-point strength measurements. the total patient population included in this study will be 60 patients.


Eligibility criteria:
inclusion criteria: * radiographic eaton stage 2 or 3 1st carpometacarpal joint arthritis * failed medical management, requesting surgical intervention exclusion criteria: * pediatric population * eaton stage 1 or 4 * medically unfit for procedure
pharmacokinetic effects of qti571 on sildenafil and bosentan in pulmonary arterial hypertension participants

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study was to investigate the effects of qti571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.


Eligibility criteria:
inclusion criteria: * participants with pulmonary arterial hypertension (pah) in world health organization (who) diagnostic group 1, with pulmonary vascular resistance \> 800 dyne\*sec\*cm\^-5, * on stable doses of bosentan and sildenafil exclusion criteria: * other diagnosis of pah in world health organization (who) diagnostic group 1 such as congenital large or small unrepaired systemic to pulmonary shunts, portal hypertension, human immunodeficiency virus (hiv) infection, glycogen storage disease, gaucher's disease, hereditary hemorrhagic teleangiectasia, hemoglobinopathies, myeloproliferative disorders, veno-occlusive pulmonary disease * significant lung diseases not related to pah * significant cardiovascular system disorders, hematological system disorders, liver insufficiency * significant diseases in other organ system. other protocol-defined inclusion/exclusion criteria may apply

Keywords: pulmonary arterial hypertension pulmonary vascular resistance imatinib bosentan sildenafil
opioid free anesthesia in thoracic surgery

Conditions: Thoracic Surgery; Analgesics, Opioid; Anesthesia, Conduction

Summary: proper assessment of pain and adequate analgesia in thoracic surgery is a challenging issue for medical practitioners. basic aspects of thoracic anaesthesia are general anesthesia, intubation with double lumen tube and separation of lung ventilation, however proper analgesia needs to be standardized. role of opioids in this clinical setting is reduced due to high risk of respiratory system complications. instead, use of opioid free anaesthesia and regional anaesthesia is proposed. the aim of this study is to compare the use of opioid anaesthesia with opioid free anaesthesia and paravertebral block.


Eligibility criteria:
inclusion criteria: * body mass index between 19-30 kg/m2, * american society of anesthesiology (asa) physical status between 1 and 3 exclusion criteria: * lack of consent * significant coagulopathy, * contraindication to drugs used in protocol * history of chronic pain, * chest wall neoplastic invasion, * previous thoracic spine surgery, * mental state preventing from effective use of pca device, * renal failure (gfr \<60 ml/min/1,73 m2)
study of airflow in the lungs using helium mri

Conditions: COPD; Healthy; Constrictive Bronchitis

Summary: computer simulations are being developed to predict air flow abnormalities in the airways of patients with lung disease. the purpose of this study is to obtain actual gas flow measurements in the lungs of healthy patients and patients with lung disease and use these measurements to validate the computer models.

the biotechnology high performance computing software applications institute (bhsai) of the department of defense (dod) is studying airflow in the lungs using computational fluid dynamics in order to characterize disease-specific airflow patterns and provide useful information for medical applications. to validate these models, they are seeking to obtain experimental data of airflow in human lungs, both healthy and diseased. an assessment of airflow can be obtained by using hyperpolarized noble gas (hng) magnetic resonance imaging (mri) or, more specifically, hyperpolarized helium-3 (hhe) mri in conjunction with flow-encoding schemes that are well-established in conventional proton mri four chronic obstructive pulmonary disease (copd) patients and four healthy subjects will undergo pulmonary function tests (pfts), computed tomography (ct) scan covering the mouth, neck, and chest, and hyperpolarized helium 3 mri. before and after the mri scans, three spirometry readings will be taken while the subject is lying in the same position as in the mr scanners. data will be analyzed by the bhsai. uva will provide the de-identified raw image data and the de-identified results of the spirometry and other tests to bhsai

Eligibility criteria:
inclusion criteria: * healthy subjects: * normal pft values: fev1 \> 90% predicted; and forced vital capacity (fvc) \> 90% predicted * normal chest x-ray (cxr) * medical history: no active pulmonary symptoms (cough, shortness of breath, sputum); negative history of pulmonary disease; negative smoking history (never smoked) * pulmonary disease subjects: * pft values: fev1/fvc \< 70% (indicative of obstruction); and 30% \< fev1 \< 50% predicted * cxr normal except hyperinflation * symptoms - chronic shortness of breath * all test subjects, healthy and with copd should have similar physical anthropometric characteristics: * similar age with age difference less than 3 years * similar height (within 3-4 inches) exclusion criteria: * any condition for which a mri procedure is contraindicated. * presence of any non-mri compatible metallic material in the body, such as pacemakers, metallic clips, etc. * likelihood of claustrophobia * chest circumference greater than that of the helium mr coil. * pregnancy, by report of subject. clinically in the department of radiology at uva, self report is used when screening patients for mr scans as well as ct scans and fluoroscopy studies. if the subject reports there is any chance of their being pregnant a urine pregnancy test will be performed prior to any imaging.

Keywords: hyperpolarized gas mri